Celldex Therapeutics Inc CLDX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/03/24 EDT
42.50quote price arrow down-0.06 (-0.14%)
Volume
25,598
Close
42.56quote price arrow up+1.70 (+4.16%)
Volume
579,354
52 week range
22.11 - 53.18
Loading...
  • Open41.91
  • Day High42.98
  • Day Low41.34
  • Prev Close40.86
  • 52 Week High53.18
  • 52 Week High Date03/04/24
  • 52 Week Low22.11
  • 52 Week Low Date10/30/23

Key Stats

  • Market Cap2.805B
  • Shares Out65.91M
  • 10 Day Average Volume0.58M
  • Dividend-
  • Dividend Yield-
  • Beta1.53
  • YTD % Change7.31

KEY STATS

  • Open41.91
  • Day High42.98
  • Day Low41.34
  • Prev Close40.86
  • 52 Week High53.18
  • 52 Week High Date03/04/24
  • 52 Week Low22.11
  • 52 Week Low Date10/30/23
  • Market Cap2.805B
  • Shares Out65.91M
  • 10 Day Average Volume0.58M
  • Dividend-
  • Dividend Yield-
  • Beta1.53
  • YTD % Change7.31

RATIOS/PROFITABILITY

  • EPS (TTM)-2.91
  • P/E (TTM)-14.63
  • Fwd P/E (NTM)-14.79
  • EBITDA (TTM)-139.034M
  • ROE (TTM)-37.45%
  • Revenue (TTM)6.883M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-2,054.76%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/06/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Celldex Therapeutics Inc

 

Profile

MORE
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is...
Karen Shoos
Non-Executive Independent Chairman of the Board
Anthony Marucci
President, Chief Executive Officer, Director
Sam Martin CPA
Chief Financial Office, Senior Vice President, Secretary
Tibor Keler Ph.D.
Executive Vice President, Chief Scientific Officer
Address
53 Frontage Road, Suite 220
Hampton, NJ
08827
United States

Top Peers

SYMBOLLASTCHG%CHG
KROS
Keros Therapeutics Inc
60.57+3.47+6.08%
DYN
Dyne Therapeutics Inc
26.08+0.08+0.31%
NTLA
Intellia Therapeutics Inc
23.60+0.33+1.42%
GERN
Geron Corp
3.93-0.02-0.51%
KURA
Kura Oncology Inc
20.63+0.04+0.19%